Skip to main content
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.

Women & Science Entrepreneurship Fund Speaker Series - Inaugural Event

 

Conversations with Women Leaders in Bioscience

Wednesday, December 2, 2020
4:00 – 5:00 PM | WEBINAR
DONATE  REGISTER


Host:

Elaine Fuchs, Ph.D.

Rebecca C. Lancefield Professor
Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development
The Rockefeller University

Inaugural Speaker:

Akinsanya, Karen

Karen Akinsanya, Ph.D.

Executive Vice President, Chief Biomedical Scientist, and Head of R&D
Schrödinger


On Wednesday, October 28 at 4:00 P.M., Dr. Elaine Fuchs will interview Dr. Karen Akinsanya about her distinguished scientific career, her innovative and exciting work at Schrödinger, and her advice to researchers about the field of biotechnology. Webinar attendees will then be able to partake in a live Q&A with Drs. Akinsanya and Fuchs.

Dr. Karen Akinsanya joined Schrödinger in 2018. She leads the company’s Discovery R&D group with responsibility for preclinical drug discovery and translational research. Dr. Akinsanya has more than 25 years of experience in academia, pharmaceutical R&D, partnerships, and licensing. She joined Merck Research Labs in 2005 and held positions of increasing responsibility in clinical pharmacology as a development team leader working on first-in-human studies through late-stage label studies before joining Discovery Preclinical & Early Development as a therapeutic area lead and then a search and evaluation lead in business development.

Dr. Akinsanya received her Ph.D. in endocrine physiology from the Royal Postgraduate Medical School at Imperial College in London. After post-doctoral training at Imperial College and the Ludwig Institute for Cancer Research (UCL), she joined Ferring Pharmaceuticals in R&D working across sites in the United Kingdom and United States. At Ferring, Dr. Akinsanya led the discovery of a family of dipeptidyl peptidases related to DPPIV and pre-clinical characterization of FDA-approved FIRMAGON® for prostate cancer.